<DOC>
	<DOC>NCT01264679</DOC>
	<brief_summary>To evaluate the efficacy and safety of episodic treatment of iron deficiency anemia (IDA) with ferumoxytol.</brief_summary>
	<brief_title>A Trial of Ferumoxytol for the Episodic Treatment of Iron Deficiency Anemia in Pediatric Subjects With Chronic Kidney Disease</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency, Chronic</mesh_term>
	<mesh_term>Anemia, Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<criteria>Key Inclusion Criteria include: 1. Subjects who have completed participation in study AMAGFERCKD251 or AMAGFERCKD252 within the past 4 weeks 2. Female subjects of childbearing potential who are sexually active must be on an effective method of birth control and agree to remain on birth control until completion of participation in the study 3. Subject and/or legal guardian is capable of understanding and complying with the protocol requirements and is available for the duration of the study Key Exclusion Criteria include: 1. Experienced a serious adverse event (SAE) related to intravenous (IV) iron therapy in study AMAGFERCKD251 or AMAGFERCKD252 2. Hemoglobin â‰¤7 g/dL</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Iron deficiency anemia, Feraheme, ferumoxytol, CKD, pediatric, dialysis-dependent, pediatric nondialysis-dependent</keyword>
</DOC>